Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 1-10 of 11

Page
per page
  1. TAK-632
    A8226 TAK-632
    Target: Raf
    Summary: Pan-RAF inhibitor,potent and selective
      ≥27.75 mg/mL
  2. GDC-0879
    A5071 GDC-0879
     1 Citation
    Target: Raf
    Summary: B-Raf inhibitor,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥16.7 mg/mL
  3. Pimasertib (AS-703026)
    A5573 Pimasertib (AS-703026)
    Target: MEK
    Summary: MEK1/2 inhibitor
      ≥21.55 mg/mL
  4. AZD8330
    A8374 AZD8330
    Target: MEK
    Summary: MEK 1/2 inhibitor
      ≥23.05 mg/mL
  5. TAK-733
    B1621 TAK-733
    Target: MEK
    Summary: MEK allosteric site inhibitor
      ≥25.2 mg/mL
  6. Dabrafenib Mesylate (GSK-2118436)
    A3347 Dabrafenib Mesylate (GSK-2118436)
    Target: Raf
    Summary: Inhibitor of BRAF(V600) mutants
      ≥30.75 mg/mL
  7. LGX818
    B1174 LGX818
    Target: Raf
    Summary: RAF inhibitor,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥13.38 mg/mL
  8. GDC-0623
    B1135 GDC-0623
    Target: MEK
    Summary: MEK1 inhibitor, potent and ATP-uncompetitive
      insoluble in H2O; ≥16.85 mg/mL
  9. Trametinib DMSO solvate
    A3887 Trametinib DMSO solvate
     1 Citation
    Target: MEK
    Summary: Allosteric MEK1/MEK2 kinase inhibitor
      insoluble in EtOH; insoluble in H2O; ≥11.2 mg/mL
  10. Vemurafenib (PLX4032, RG7204)
    A3004 Vemurafenib (PLX4032, RG7204)
     9 Citation
    Target: Raf
    Summary: BRAF kinase inhibitor
      ≥24.5 mg/mL

Items 1-10 of 11

Page
per page
Relate Categories
Now Shopping by
  1. Category MAPK Signaling Remove This Item
  2. Reported Experiments Animal Experiments Remove This Item
  3. Related Disease Melanoma Remove This Item
Clear All